Despite the low recurrence frequency, this fusion supports repurposing drugs developed against the NAB2-STAT6 or the EGR pathway in SFTs as a potential alternative or adjuvant therapy for patients with genetically similar gliomas. This evidence concerns the gene NAB2 and central nervous system cancer.